OneFifteen in Dayton aims to collect insights on 1,000 annual outpatient addicts
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email firstname.lastname@example.org to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
On the corner of Hopeland Street in Dayton, Ohio — the epicentre of the US opioid epidemic — an old tool factory has been revived. Painted in bright greens and whites, and furnished with comfy chairs and a ping-pong table, the OneFifteen campus looks more like a tech company than a healthcare facility. In fact the centre, which will open this summer, represents the first attempt by Verily, Google’s life sciences sister company, to bring a data-driven approach to treating patients with opioid use disorder. Verily, which was spun out of the “moon shot” unit of Google’s parent company Alphabet four years ago and recently raised $1bn in a round led by private equity firm Silver Lake, hopes that the insights it gains from the 1,000 annual outpatients it hopes to treat at OneFifteen will transform the care of the more than 2m Americans suffering from opioid use disorder.